X
- No products in the list
The Pneumocystis jirovecii PCR Detection Kit is a highly sensitive real-time qPCR assay designed for the qualitative detection of P. jirovecii DNA in human clinical samples. Using advanced hydrolysis probe (TaqMan®) technology, the assay enables rapid and reliable identification of this opportunistic fungal pathogen, which is a major cause of severe pneumonia in immunocompromised patients.
The kit targets conserved genomic regions of P. jirovecii, ensuring accurate detection even at low DNA concentrations. A built-in internal control system verifies DNA extraction quality and identifies potential PCR inhibition, supporting confident and reproducible results.
Optimized as a one-step qPCR workflow with ready-to-use master mix and hot-start technology, the assay minimizes handling errors and non-specific amplification. It is compatible with most commonly used real-time PCR platforms, making it suitable for routine diagnostic and clinical laboratory use.
This kit is an in-vitro diagnostic real-time PCR assay developed for the qualitative detection of Pneumocystis jirovecii DNA. The assay uses hydrolysis probe-based detection to ensure high specificity and sensitivity in identifying fungal DNA in clinical samples.
The master mix contains specific primers and probes for P. jirovecii along with an internal control, enabling simultaneous detection and validation of sample integrity and amplification efficiency.
Pneumocystis jirovecii is a fungal pathogen responsible for Pneumocystis pneumonia (PCP), a serious and potentially life-threatening infection primarily affecting immunocompromised individuals, including patients with HIV/AIDS, cancer, or those receiving immunosuppressive therapies.
Transmission occurs via airborne droplets, and while healthy individuals may carry the organism asymptomatically, they can act as reservoirs contributing to its spread. In susceptible individuals, infection can lead to severe respiratory illness characterized by fever, persistent dry cough, dyspnoea (shortness of breath), and, in advanced cases, respiratory failure.
Historically, P. jirovecii gained clinical significance during World War II and later became widely recognized during the HIV/AIDS epidemic in the 1980s as a leading cause of opportunistic infections. Early and accurate diagnosis is critical, as delayed treatment significantly increases morbidity and mortality.
The assay enables rapid detection of P. jirovecii DNA in respiratory and blood samples, including sputum, bronchoalveolar lavage (BAL), bronchial washings, and blood. The use of real-time PCR allows for sensitive detection even in low fungal load samples.
Hydrolysis probe technology ensures precise target detection, with fluorescence generated in the FAM channel indicating the presence of P. jirovecii DNA. An internal control detected via the HEX channel confirms sample quality and absence of PCR inhibitors.
The ready-to-use format reduces hands-on time, while hot-start and UDG technologies enhance assay reliability by preventing non-specific amplification and carryover contamination.
Instructions for Use